CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00768144
NCT00768144Phase 2Completed
CompareCT.gov

A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Dana-Farber Cancer Institute·interventional·Posted Oct 7, 2008·Updated Aug 24, 2018

In Brief

A Phase 2 clinical trial evaluating Sunitinib for Ovarian Cancer and 2 related conditions. Completed, enrolled 36 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 7, 2008
Enrollment StartSep 1, 2008
Primary CompletionMay 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.7 years ago

Interventions

Sunitinibdrug